Augustine Therapeutics
BelgiumEntry
2025
Hold
1yr
Status
Active
Who owns Augustine Therapeutics?
Augustine Therapeutics is currently owned by Jeito Capital through Jeito II (2026 vintage), since 2025. Across its history, Augustine Therapeutics has been through 4 private equity ownership periods, detailed in the timeline below.
Hand-verified · updated 2026-04-21
Key takeaways
- ·Co-held by AdBio Partners, Novo Holdings, Asabys Partners and Jeito Capital since 2019.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
4 ownership periods · co-invest detected
Active
Co-invest · 4 holders · 2019 · present
AdBio PartnersActive
2019 · present(7yr) · AFB Fund II · 2021 · VC
Asabys PartnersActive
2024 · present(2yr) · Sabadell Asabys Health Innovation Investments II · 2023 · Life Sciences VC
Novo HoldingsActive
2024 · present(2yr) · Novo Holdings Venture Investments · 1999 · VC
Jeito CapitalActive
2025 · present(1yr) · Jeito II · 2026 · VC
More from Jeito II
Other portfolio companies in the same fund.
Denmark
US
France
NetherlandsMore PE-backed in Biotech
Comparable biotech deals from other GPs.
Track Augustine Therapeutics
Save this record to your watchlist and pick up your research where you left off. No spam.
Who could buy Augustine Therapeutics?
5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.
Find likely buyersGet the full record on Augustine Therapeutics.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
Already a member? Sign in
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue